No connection

Search Results

IMCR vs UFPT

IMCR
Immunocore Holdings plc
BEARISH
Price
$31.05
Market Cap
$1.57B
Sector
Healthcare
AI Confidence
85%
UFPT
UFP Technologies, Inc.
NEUTRAL
Price
$198.68
Market Cap
$1.53B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
IMCR
--
UFPT
22.71
Forward P/E
IMCR
-22.02
UFPT
17.35
P/B Ratio
IMCR
4.13
UFPT
3.62
P/S Ratio
IMCR
3.94
UFPT
2.54
EV/EBITDA
IMCR
-51.28
UFPT
14.86

Profitability

Gross Margin
IMCR
96.53%
UFPT
28.27%
Operating Margin
IMCR
0.03%
UFPT
14.1%
Profit Margin
IMCR
-8.88%
UFPT
11.33%
ROE
IMCR
-9.58%
UFPT
17.82%
ROA
IMCR
-1.54%
UFPT
9.05%

Growth

Revenue Growth
IMCR
24.3%
UFPT
3.4%
Earnings Growth
IMCR
--
UFPT
6.8%

Financial Health

Debt/Equity
IMCR
1.15
UFPT
0.36
Current Ratio
IMCR
4.04
UFPT
2.69
Quick Ratio
IMCR
3.91
UFPT
1.45

Dividends

Dividend Yield
IMCR
--
UFPT
--
Payout Ratio
IMCR
0.0%
UFPT
0.0%

AI Verdict

IMCR BEARISH

IMCR exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational deterioration. While the company maintains an impressive gross margin of 96.53% and positive revenue growth of 24.3%, these are offset by a catastrophic year-over-year EPS decline of 452.9% and a bearish insider sentiment. There is a stark disconnect between the aggressive analyst target price of $63.86 and the actual deterministic data, which suggests a high-risk profile characterized by consistent earnings misses and insider liquidation.

Strengths
Exceptional gross margins (96.53%) typical of high-value biotech products
Strong short-term liquidity with a current ratio of 4.04
Consistent positive revenue growth (24.3% YoY)
Risks
Critical financial health failure (Piotroski F-Score 1/9)
Severe earnings collapse with YoY EPS growth of -452.9%
Bearish insider activity with $4.35M in sales and zero buys
UFPT NEUTRAL

UFPT exhibits exceptional fundamental health with a perfect Piotroski F-Score of 9/9 and a very conservative debt profile. However, the stock is currently trading at a significant premium, with a current price of $198.68 well above its Graham Number ($104.01) and Intrinsic Value ($150.50). While the earnings track record is stellar, organic growth is sluggish at 1.5%, and high customer concentration (45.8% from two clients) presents a systemic risk. The combination of a high PEG ratio (3.80) and bearish insider activity suggests the stock is currently overvalued despite its operational excellence.

Strengths
Perfect Piotroski F-Score (9/9) indicating peak financial health
Strong liquidity with a Current Ratio of 2.69 and low Debt/Equity of 0.36
Exceptional earnings track record with consistent beats over 25 quarters
Risks
Severe customer concentration: Intuitive Surgical and Stryker account for 45.8% of sales
Weak organic growth (1.5%) suggesting reliance on acquisitions for top-line expansion
High valuation relative to growth (PEG Ratio of 3.80)

Compare Another Pair

IMCR vs UFPT: Head-to-Head Comparison

This page compares Immunocore Holdings plc (IMCR) and UFP Technologies, Inc. (UFPT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile